[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636166":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":35,"locations":41,"responsibleParty":301,"collaborators":27,"id":303,"slug":304,"hasResults":305,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":305,"sex":311,"minAge":312,"maxAge":27,"enrollmentInfo":313,"targetDuration":27,"studyType":316,"phases":317,"briefSummary":319,"conditions":320,"keywords":329,"overallStatus":44,"whyStopped":27,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},{"fullName":5,"class":6},"Immuneering Corporation","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Atebimetinib + mGnP","EXPERIMENTAL","Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma",[13,14],"Drug: Atebimetinib","Drug: mGnP",{"label":16,"type":17,"description":18,"interventionNames":19},"GnP","ACTIVE_COMPARATOR","Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma",[20],"Drug: GnP",[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Atebimetinib","Once daily oral tablets",[9],null,{"type":23,"name":16,"description":29,"armGroupLabels":30,"otherNames":27},"Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion",[16],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":27},"mGnP","Biweekly intravenous infusions of chemotherapy (gemcitabine and nab-paclitaxel)",[9],[36],{"name":37,"role":38,"phone":39,"phoneExt":27,"email":40},"Immuneering Study Team","CONTACT","860-321-1302","clinicaltrials@immuneering.com",[42,60,73,86,100,110,123,137,151,165,177,191,205,219,232,245,259,273,288],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"City of Hope","RECRUITING","Phoenix","Arizona","85338","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-112.07404,33.44838,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":27,"phoneExt":27,"email":59},"Khaled Abouelezz, MD","phxresearch@coh.org",{"facility":43,"status":44,"city":61,"state":62,"zip":63,"country":48,"countryCode":49,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Duarte","California","91010",{"type":51,"coordinates":65},[66,67],-117.97729,34.13945,{"lat":67,"lon":66},[70],{"name":71,"role":38,"phone":27,"phoneExt":27,"email":72},"Jalene Tangen","jtangen@coh.org",{"facility":74,"status":44,"city":75,"state":76,"zip":77,"country":48,"countryCode":49,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Piedmont Healthcare","Atlanta","Georgia","30318",{"type":51,"coordinates":79},[80,81],-84.38798,33.749,{"lat":81,"lon":80},[84],{"name":85,"role":38,"phone":27,"phoneExt":27,"email":27},"Eyal Meiri, MD",{"facility":87,"status":44,"city":88,"state":89,"zip":90,"country":48,"countryCode":49,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Illinois Cancer Specialists","Arlington Heights","Illinois","60005",{"type":51,"coordinates":92},[93,94],-87.98063,42.08836,{"lat":94,"lon":93},[97],{"name":98,"role":38,"phone":27,"phoneExt":27,"email":99},"Study Team","aearles@illinoiscancercare.com",{"facility":43,"status":44,"city":101,"state":89,"zip":102,"country":48,"countryCode":49,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Chicago","60099",{"type":51,"coordinates":104},[105,106],-87.65005,41.85003,{"lat":106,"lon":105},[109],{"name":71,"role":38,"phone":27,"phoneExt":27,"email":72},{"facility":111,"status":44,"city":112,"state":89,"zip":113,"country":48,"countryCode":49,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"OSF Medical Center","Peoria","61603",{"type":51,"coordinates":115},[116,117],-89.58899,40.69365,{"lat":117,"lon":116},[120],{"name":121,"role":38,"phone":27,"phoneExt":27,"email":122},"Peyton Swearingen","peyton.o.swearingen@osfhealthcare.org",{"facility":124,"status":44,"city":125,"state":126,"zip":127,"country":48,"countryCode":49,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Missouri Cancer Associates","Columbia","Missouri","65201",{"type":51,"coordinates":129},[130,131],-92.33407,38.95171,{"lat":131,"lon":130},[134],{"name":135,"role":38,"phone":27,"phoneExt":27,"email":136},"Crystal Johnson","crystal.johnson@usoncology.com",{"facility":138,"status":44,"city":139,"state":140,"zip":141,"country":48,"countryCode":49,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Comprehensive Cancer Centers","Las Vegas","Nevada","89169",{"type":51,"coordinates":143},[144,145],-115.13722,36.17497,{"lat":145,"lon":144},[148],{"name":149,"role":38,"phone":27,"phoneExt":27,"email":150},"Lindsay Kondo","lindsay.kondo@usoncology.com",{"facility":152,"status":44,"city":153,"state":154,"zip":155,"country":48,"countryCode":49,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Regional Cancer Care","Belleville","New Jersey","07109",{"type":51,"coordinates":157},[158,159],-74.15014,40.79371,{"lat":159,"lon":158},[162],{"name":163,"role":38,"phone":27,"phoneExt":27,"email":164},"Denise Johnstone","denise.johnstone@regionalcancercare.org",{"facility":166,"status":44,"city":167,"state":167,"zip":168,"country":48,"countryCode":49,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"NYU Langone Health","New York","10016",{"type":51,"coordinates":170},[171,172],-74.00597,40.71427,{"lat":172,"lon":171},[175],{"name":98,"role":38,"phone":27,"phoneExt":27,"email":176},"ct.gov@nyulangone.org",{"facility":178,"status":44,"city":179,"state":180,"zip":181,"country":48,"countryCode":49,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Taylor Cancer Research Center","Maumee","Ohio","43537",{"type":51,"coordinates":183},[184,185],-83.65382,41.56283,{"lat":185,"lon":184},[188],{"name":189,"role":38,"phone":27,"phoneExt":27,"email":190},"Stephanie Ambrose","sambrose@tcrcpt.org",{"facility":192,"status":44,"city":193,"state":194,"zip":195,"country":48,"countryCode":49,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Thomas Jefferson University","Philadelphia","Pennsylvania","19107",{"type":51,"coordinates":197},[198,199],-75.16362,39.95238,{"lat":199,"lon":198},[202],{"name":203,"role":38,"phone":27,"phoneExt":27,"email":204},"Zuly Delgado","Zuleika.delgado@jefferson.edu",{"facility":206,"status":44,"city":207,"state":208,"zip":209,"country":48,"countryCode":49,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":51,"coordinates":211},[212,213],-86.78444,36.16589,{"lat":213,"lon":212},[216],{"name":217,"role":38,"phone":27,"phoneExt":27,"email":218},"Meredith Pelster, MD","SCRI.ResearchReferrals@scresearch.net",{"facility":220,"status":44,"city":221,"state":222,"zip":223,"country":48,"countryCode":49,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Texas Oncology - San Antonio","San Antonio","Texas","78240",{"type":51,"coordinates":225},[226,227],-98.49363,29.42412,{"lat":227,"lon":226},[230],{"name":231,"role":38,"phone":27,"phoneExt":27,"email":27},"Angel Mier-Hicks, MD",{"facility":233,"status":44,"city":234,"state":222,"zip":235,"country":48,"countryCode":49,"cosmosGeoPoint":236,"geoPoint":240,"contacts":241},"Texas Oncology Gulf Coast","Webster","77598",{"type":51,"coordinates":237},[238,239],-95.11826,29.53773,{"lat":239,"lon":238},[242],{"name":243,"role":38,"phone":27,"phoneExt":27,"email":244},"Tara Gray","tara.gray@usoncology.com",{"facility":246,"status":44,"city":247,"state":248,"zip":249,"country":48,"countryCode":49,"cosmosGeoPoint":250,"geoPoint":254,"contacts":255},"Blue Ridge Cancer Care","Blacksburg","Virginia","24060",{"type":51,"coordinates":251},[252,253],-80.41394,37.22957,{"lat":253,"lon":252},[256],{"name":257,"role":38,"phone":27,"phoneExt":27,"email":258},"Natasha Holt","natasha.holt@usoncology.com",{"facility":260,"status":44,"city":261,"state":262,"zip":263,"country":48,"countryCode":49,"cosmosGeoPoint":264,"geoPoint":268,"contacts":269},"Northwest Cancer Specialists","Vancouver","Washington","98684",{"type":51,"coordinates":265},[266,267],-122.66149,45.63873,{"lat":267,"lon":266},[270],{"name":271,"role":38,"phone":27,"phoneExt":27,"email":272},"Susan Papenfuse","susan.papenfuse@usoncology.com",{"facility":274,"status":44,"city":275,"state":276,"zip":277,"country":278,"countryCode":279,"cosmosGeoPoint":280,"geoPoint":284,"contacts":285},"Calvary Mater Newcastle","Waratah","New South Wales","2298","Australia","AU",{"type":51,"coordinates":281},[282,283],151.72647,-32.90667,{"lat":283,"lon":282},[286],{"name":287,"role":38,"phone":27,"phoneExt":27,"email":27},"Prajwol Shrestha, MD",{"facility":289,"status":44,"city":290,"state":291,"zip":292,"country":278,"countryCode":279,"cosmosGeoPoint":293,"geoPoint":297,"contacts":298},"Icon Cancer Centre - Chermside","Chermside","Queensland","4032",{"type":51,"coordinates":294},[295,296],153.03062,-27.38472,{"lat":296,"lon":295},[299],{"name":300,"role":38,"phone":27,"phoneExt":27,"email":27},"Chun Gan, MD",{"type":302,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100636166","phase-3-atebimetinib--gnp-as-a-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100636166",false,"NCT07562152","Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","MAPKeeper 301","Inclusion Criteria:\n\n* Must be ≥18 years of age\n* Must have confirmed diagnosis according to AJCC staging as follows:\n\n  * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants must be treatment naive as follows:\n\n  * First-line PDAC participants will have received no previous systemic anti-cancer therapy\n* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria\n* Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values\n\nExclusion Criteria:\n\n* Inability to swallow oral medications\n* Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma\n* Participants with only locally advanced disease\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases","ALL","18 Years",{"count":314,"type":315},510,"ESTIMATED","INTERVENTIONAL",[318],"PHASE3","The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.",[321,322,323,324,325,326,327,328],"Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma",[330,331,332,333,334,335,336,337],"mitogen-activated protein kinase (MAPK)","MAPK","MEK","metastatic cancer","gemcitabine","nab-paclitaxel","nab-p","atebimetinib","2026-06-18",{"date":340,"type":341},"2026-06-22","ACTUAL",{"date":343,"type":315},"2026-06",{"date":345,"type":315},"2029-02",{"name":5,"class":6},19]